BRAF and non-small cell lung carcinoma: Meanwhile, combined with the analysis of immune-related scores (GEP scores, IFN-γsignatures, T cell markers, and chemokines) in our results, we could infer that BRAF mutation may result in balanced immunomodulatory effects and did not affect the therapeutic responses to ICIs in NSCLC patients.